- Investing.com
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Analyst Perspectives | Price targets range from $150 to $220, with an average of $172.50, reflecting varied views on Repligen's growth potential and market position |
Market Expansion | Explore Repligen's growth from a $4B addressable market in 2020 to $12B in 2024, driven by new modalities and digitization initiatives |
Financial Resilience | Q1 2025 revenue surpassed expectations at $169.2M, with revised full-year guidance of $695M-$720M, despite earnings per share missing forecasts |
Bioprocessing Pionee | Repligen leads the bioprocessing industry with innovative products and strategic acquisitions, navigating market recovery and industry challenges |
Metrics to compare | RGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | 142.9x | 29.9x | −0.5x | |
PEG Ratio | 0.48 | 0.73 | 0.00 | |
Price / Book | 3.3x | 2.3x | 2.6x | |
Price / LTM Sales | 9.5x | 1.8x | 3.2x | |
Upside (Analyst Target) | 40.7% | 55.5% | 51.4% | |
Fair Value Upside | Unlock | 21.0% | 7.1% | Unlock |